StreetSmart Live! Presents Michael Ballanger on 10/26/2020. Learn More
News Update

Biopharma White Paper Posits FDA Approval of Biogen's Alzheimer's Drug Likely Next Month

News Update
  ()
ProMIS Neurosciences cites "unequivocally positive data" and encouraging FDA actions with respect to the therapeutic. read more >

Align Technology Shares Head Straight Up on 20.9% Q3 Revenue Growth as Firm Celebrates its 9 Millionth Invisalign Patient

  ()
Shares of Align Technology traded 35% higher and climbed to a new 52-week high after the company reported Q3/20 financial results that included a 20.9% YoY increase in net revenues. read more >
News Update

Biotech Secures Supplier of Psilocybin, Other Psychedelics

News Update
  ()
Revive Therapeutics will use these products in future studies and clinical trials. read more >

Aptinyx Shares Trade 17% Higher on Positive Top-Line Data in Phase 2 PTSD Trial

  ()
Aptinyx shares set a new 52-week high price after the company reported statistically significant, top-line data from its Phase 2 Study of NYX-783 in patients diagnosed with post-traumatic stress disorder. read more >

With Bases Loaded, NervGen Swings for the Fences in Traumatic Brain Injury

Contributed Opinion
  ()
Is there anything intracellular sigma peptide, the company's lead agent, can't do, asks Dr. KSS, MD, PhD, editor-in-chief of BioPub.co. read more >

BioSpecifics Technologies Agrees to $658 Million Buyout Offer from Endo Pharmaceuticals

  ()
Biospecifics Technologies shares traded 45% higher after the company reported that it agreed to be acquired by Endo Pharmaceuticals for $88.50 per share in an all cash transaction. read more >

Organogenesis Shares Rise 20% on Q3 Net Revenue Growth and FY Guidance

  ()
Shares of Organogenesis Holdings traded higher after the company reported preliminary Q3/20 financial results demonstrating a 55% increase in year-over-year revenue. read more >

Allscripts Agrees to Sell Its CarePort Health Business for $1.35 Billion

  ()
Shares of Allscripts Healthcare Solutions traded 30% higher after the company reported it has agreed to sell its CarePort Health business to WellSky Corp. for $1.35 billion. read more >

Phase 3 COVID-19 Study of Firm's Stem Cell Product Exceeds 50% Enrollment

Research Report
  ()
The study design and goals and Mesoblast's next steps are reviewed in a Dawson James Securities report. read more >
News Update

Biopharma Announces Pulmonary Fibrosis Trial Now 25% Enrolled

News Update
  ()
Five sites in Australia and New Zealand are participating in this study of Algernon Pharmaceuticals' drug. read more >
News Update

Life Sciences Firm Lands Record 4 Metric Tons Order for Antibiotic-Free Feedstock

News Update
  ()
Avivagen Inc. reported that it has received a record purchase order for its OxC-beta™ product from UNAHCO. read more >

Altimmune Publishes Compelling Preclinical Data for Intranasal COVID-19 Vaccine Candidate

  ()
Altimmune Inc. shares traded 12% higher after the company published preclinical studies conducted together with the University of Alabama at Birmingham for AdCOVID, its intranasal COVID-19 vaccine candidate. read more >

StreetSmart Live! Presents Algernon Pharmaceuticals

  ()
Algernon Pharmaceuticals CEO Christopher Moreau and guests fund manager Steve Palmer, Dr. Mark Swaim and Tony Pullen discuss the company's upcoming catalysts and events. read more >

Expert Investing Ideas

"SPR is the number one cannabis stock to own today."

–Cynthia Berryman, Financial News Now


"We expect PMN to forge a licensing deal in Q2/19 or Q3/19."

–André Uddin, Mackie Research Capital


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
Last StreetSmart Live! Show
NASDAQ Biotech ARCA Pharmaceutical

CareDx Shares Trade Up 15% After Announcing 57% YoY Increase in Q3 Revenue

  ()
CareDx shares established a new 52-week high after the company reported that preliminary revenue in Q3/20 increased 57% year-over-year to $53.0 million. read more >

Ocular Therapeutix Shares Rise 25% After Firm Reports 250% Sequential Increase in Q3 Revenue

  ()
Ocular Therapeutix shares reached a new 52-week high after the company reported that preliminary net product revenue increased to $5.8-5.9 million during Q3/20, representing a more than 250% increase over the previous quarter. read more >

Immunotherapy Firm Announces Positive Top-Line Trial Results for Severe and Critical COVID-19 Patients

Research Report
  ()
The study data and potential near-term catalysts for Enlivex Therapeutics are covered in an H.C. Wainwright & Co. report. read more >